The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen
Open accessAbstract
Prostate cancer (PCa) is the second leading cause of cancer-related death in American men. Positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease, detection of metastatic lesions and, ultimately, for predicting the aggressiveness of disease. Prostate-specific membrane antigen (PSMA) is a well-characterized imaging biomarker of PCa. Because PSMA levels are directly related to androgen independence, metastasis and progression, PSMA could prove an important target for the development of new radiopharmaceuticals for PET. Preclinical data for new PSMA-based radiotracers are discussed and include new (89)Zr- and (64)Cu-labeled anti-PSMA antibodies and antibody fragments, (64)Cu-labeled aptamers, and (11)C-, (18)F-, (68)Ga-, (64)Cu-, and (86)Y-labeled low molecular weight inhibitors of PSMA. Several of these agents, namely (68)Ga- HBED-CC conjugate 15, (18)F-DCFBC 8, and BAY1075553 are particularly promising, each having detected sites of PCa in initial clinical studies. These early clinical results suggest that PET/CT using PSMA-targeted agents, especially with compounds of low molecular weight, will make valuable contributions to the management of PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase
Davis, M. I., Bennett, M. J., Thomas, L. M., & Bjorkman, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502101102 · Cited by 296
Cited by
Maurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H.-J., Heck, M., Kübler, H., Beer, A. J., et al. (2016) · Journal of Urology · doi:10.1016/j.juro.2015.12.025 · Cited by 779
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer
Eiber, M., Weirich, G., Holzapfel, K., Souvatzoglou, M., Haller, B., Rauscher, I., Beer, A. J., Wester, H.-J., Gschwend, J., Schwaiger, M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.053 · Cited by 568
Afshar-Oromieh, A., Hetzheim, H., Kratochwil, C., Benesova, M., Eder, M., Neels, O. C., Eisenhut, M., Kübler, W., Holland-Letz, T., Giesel, F. L., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161299 · Cited by 427
von Eyben, F. E., Picchio, M., von Eyben, R., Rhee, H., & Bauman, G. (2018) · European Urology Focus · doi:10.1016/j.euf.2016.11.002 · Cited by 257
Metadata
- Authors
- Mease, R. C., Foss, C. A., & Pomper, M. G.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-05-01
- Volume
- 13
- Issue
- 8
- Pages
- 951-962
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2103832652
- Cited by
- 185
- References
- 3
- FWCI
- 17.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen. https://app.cochat.ai/papers/10.2174/1568026611313080008
- The paper
- Mease, R. C., Foss, C. A., & Pomper, M. G. (2013). PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/1568026611313080008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.